Home/ARC Therapies/横山雅彦 (Masahiko Yokoyama)

横雅

横山雅彦 (Masahiko Yokoyama)

CFO

Therapeutic Areas

ARC Therapies Pipeline

Drug	Indication	Phase
ATLL Cell Therapy	Adult T-cell Leukemia/Lymphoma (ATLL)	Preclinical
YB328 Microbiome Program	Cancer Immunotherapy	Research

Leadership Team at ARC Therapies

鈴木蘭美 (Ranmi Suzuki)

CEO, Representative Director, President

渡邊慶介 (Keisuke Watanabe)

Director, National Cancer Center Principal Investigator

前田優香 (Yuka Maeda)

Director, National Cancer Center Unit Leader

武本行弘 (Yukihiro Takemoto)

View full ARC Therapies profile